June 23, 2024
Intramuscular Vaccine Adjuvants Market

Rising Demand For Enhanced Vaccine Efficacy Projected To Boost Growth Of Intramuscular Vaccine Adjuvants Market

Intramuscular vaccine adjuvants are substances that are added to vaccines to enhance the immune response and create long-lasting immunity against infections. These adjuvants stimulate innate immunity and helps body build stronger and prolonged adaptive immunity against target pathogens. Adjuvants boost and modulates the immune response induced by vaccination and helps elicit immunological memory. Common intramuscular adjuvants used include aluminum salts, oil-in-water emulsions, liposomes etc. These adjuvants improves vaccine efficacy and reduces number of doses and amount of antigen required per vaccination.

The global Intramuscular Vaccine Adjuvants Market is estimated to be valued at US$ 694.19 Mn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the key trends in intramuscular vaccine adjuvants market is growing focus on development of novel adjuvants to address current challenges. Efforts are ongoing for development of adjuvants that can induce robust immune response, require lower antigen dose and help developing thermostable vaccines. Researchers are exploring newer technologies such as pathogen associated molecular patterns, saponin-based adjuvants, mineral salts and toll-like receptor agonists for safe and effective vaccine adjuvants. Another trend is growing adoption of thermostable intramuscular vaccine adjuvants. Given challenges in cool chain infrastructure in developing countries, focus on ambient temperature stable vaccines is increasing. Advanced oil-in-water emulsion and mineral salt based adjuvants are being explored and developed to allow vaccine thermostability.

Porter’s Analysis

Threat of new entrants: The biotechnology and pharmaceutical industries require huge capital investments for R&D and clinical trials. These high entry barriers protect existing players from new competition.

Bargaining power of buyers: Buyers have moderate bargaining power as intramuscular vaccine adjuvants have few substitutes and are essential for developing new vaccines. However, large pharmaceutical companies can negotiate better prices.

Bargaining power of suppliers: A few global players dominate the supply of intramuscular adjuvants. This gives them significant power to influence prices. Suppliers may integrate backwards to capture more profits.

Threat of new substitutes: No major substitute exists for intramuscular adjuvants currently. Oral adjuvants are being researched but are not proven for all vaccines. This protects intramuscular adjuvants from substitution.

Competitive rivalry: Major players invest heavily in R&D to develop novel adjuvant formulations and delivery systems. Partnerships and mergers increase as firms try to gain expertise and commercialize new products faster.

Key Takeaways

The Global Intramuscular Vaccine Adjuvants Market  Demand is expected to witness high growth, exhibiting CAGR of 6.7% over the forecast period, due to increasing focus on developing vaccines for emerging disease areas like COVID-19, malaria, tuberculosis etc.

Regionally, North America dominated the market in 2023 due to presence of major adjuvant companies and strong government support for vaccine development. However, Asia Pacific is anticipated to be the fastest growing market owing to rising healthcare expenditures, increasing disease awareness and growing research activities in countries like China and India.

Key players operating in the Intramuscular Vaccine Adjuvants market are Novavax, Inc., Adjuvance Technologies, Inc., Invivogen, Vaxine Pty Ltd., SEPPIC, SPI Pharma, Inc., Agenus Inc., Avanti Polar Lipids, Inc. and CSL Limited. Major players are focusing on developing novel oil-in-water adjuvant systems and patenting innovative vaccine formulations

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it